A guide for stakeholders preparing for the rollout of the ring to coordinate and streamline access to the ring everywhere it’s needed.
Stories from implementers rolling out PrEP: a look at some real world obstacles and the tools and insights to overcome them.
The Prevention Product Manager (PMM) and Jhpiego convened think tanks to discuss options for defining and measuring PrEP continuation. Recommendations from the think tank included modifications to current PrEP indicators, recognizing that a single definition of correct or effective use might not be possible given fluctuating and variable HIV risk.
AVAC enthusiastically welcomes the news that another trial of the long-acting, injectable antiretroviral cabotegravir (CAB-LA) for HIV prevention for HIV pre-exposure prophylaxis (PrEP) has demonstrated safety and efficacy, this time among cisgender women.